Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controll...
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
About this item
Full title
Author / Creator
Ratziu, V. , de Guevara, L. , Safadi, R. , Poordad, F. , Fuster, F. , Flores-Figueroa, J. , Arrese, M. , Fracanzani, Anna L. , Ben Bashat, D. , Lackner, K. , Gorfine, T. , Kadosh, S. , Oren, R. , Halperin, M. , Hayardeny, L. , Loomba, R. , Friedman, S. , Sanyal, Arun J. , ARREST investigator study group and the ARREST investigator study group
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
Nonalcoholic steatohepatitis (NASH), a chronic liver disease without an approved therapy, is associated with lipotoxicity and insulin resistance and is a major cause of cirrhosis and hepatocellular carcinoma. Aramchol, a partial inhibitor of hepatic stearoyl-CoA desaturase (SCD1) improved steatohepatitis and fibrosis in rodents and reduced steatosi...
Alternative Titles
Full title
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
Authors, Artists and Contributors
Author / Creator
de Guevara, L.
Safadi, R.
Poordad, F.
Fuster, F.
Flores-Figueroa, J.
Arrese, M.
Fracanzani, Anna L.
Ben Bashat, D.
Lackner, K.
Gorfine, T.
Kadosh, S.
Oren, R.
Halperin, M.
Hayardeny, L.
Loomba, R.
Friedman, S.
Sanyal, Arun J.
ARREST investigator study group
the ARREST investigator study group
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_hal_primary_oai_HAL_hal_03520782v1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_03520782v1
Other Identifiers
ISSN
1078-8956
E-ISSN
1546-170X,1744-7933
DOI
10.1038/s41591-021-01495-3
